Evidence map›Paper›PMID 34332533›Full record

ArticleBMC gastroenterology2021

Study protocol P-MAPS: microbiome as predictor of severity in acute pancreatitis-a prospective multicentre translational study.

C Ammer-Herrmenau, T Asendorf, G Beyer, S M Buchholz, S Cameron, M Damm, F Frost, R Henker, R Jaster, V Phillip and 9 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04777812 (Pancreatitis - Microbiome As Predictor of Severity), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04777812 nacompletednot on this map

Pancreatitis - Microbiome As Predictor of Severity

TypeinterventionalSponsorUniversity Medical Center GoettingenRan2020 to 2024Enrolled424ConditionsAcute PancreatitisArmsRectal and buccal swabs
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 1 country.

C Ammer-HerrmenauDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, Robert-Kochsstraße 40, 37075, Göttingen, Germany.
T AsendorfDepartment of Medical Statistics, University Medical Center, Göttingen, Germany.
G BeyerDepartment of Medicine II, University Hospital, LMU Munich, Munich, Germany.
S M BuchholzDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, Robert-Kochsstraße 40, 37075, Göttingen, Germany.
S CameronDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, Robert-Kochsstraße 40, 37075, Göttingen, Germany.
M DammDepartment of Medicine I, University Hospital Halle, Halle, Germany.
F FrostDepartment of Medicine A, University Medicine Greifswald, Greifswald, Germany.
R HenkerDivision of Gastroenterology, Medical Department II, University Hospital of Leipzig, Leipzig, Germany.
R JasterDepartment of Medicine II, University Hospital Rostock, Rostock, Germany.
V PhillipDepartment of Medicine II, University Hospital rechts der Isar, Technical University Munich, Munich, Germany.
M PlaczekDepartment of Medical Statistics, University Medical Center, Göttingen, Germany.
C RateiDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, Robert-Kochsstraße 40, 37075, Göttingen, Germany.
S SirtlDepartment of Medicine II, University Hospital, LMU Munich, Munich, Germany.
T van den BergDepartment of Medical Bioinformatics, University Medical Center, Göttingen, Germany.
M J WeingartenDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, Robert-Kochsstraße 40, 37075, Göttingen, Germany.
J WoitallaDepartment of Medicine II, University Hospital Rostock, Rostock, Germany.
J MayerleDepartment of Medicine II, University Hospital, LMU Munich, Munich, Germany.
V EllenriederDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, Robert-Kochsstraße 40, 37075, Göttingen, Germany.
A NeesseDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, Robert-Kochsstraße 40, 37075, Göttingen, Germany. albrecht.neesse@med.uni-goettingen.de.
University of Göttingen · DEUniversitätsmedizin Göttingen · DELudwig-Maximilians-Universität München · DEUniversity of Rostock · DEKlinikum rechts der Isar · DELMU Klinikum · DEUniversitätsmedizin Greifswald · DEUniversity Hospital in Halle · DEUniversity Hospital Leipzig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute pancreatitis (AP) is an inflammatory disorder that causes a considerable economic health burden. While the overall mortality is low, around 20% of patients have a complicated course of disease resulting in increased morbidity and mortality. There is an emerging body of evidence that the microbiome exerts a crucial impact on the pathophysiology and course of AP. For several decades multiple clinical and laboratory parameters have been evaluated, and complex scoring systems were developed to predict the clinical course of AP upon admission. However, the majority of scoring systems are determined after several days and achieve a sensitivity around 70% for early prediction of severe AP. Thus, continued efforts are required to investigate reliable biomarkers for the early prediction of severity in order to guide early clinical management of AP patients.

methodsWe designed a multi-center, prospective clinical-translational study to test whether the orointestinal microbiome may serve as novel early predictor of the course, severity and outcome of patients with AP. We will recruit 400 AP patients and obtain buccal and rectal swabs within 72 h of admission to the hospital. Following DNA extraction, microbiome analysis will be performed using 3rd generation sequencing Oxford Nanopore Technologies (ONT) for 16S rRNA and metagenomic sequencing. Alpha- and beta-diversity will be determined and correlated to the revised Atlanta classification and additional clinical outcome parameters such as the length of hospital stay, number and type of complications, number of interventions and 30-day mortality. DISCUSSION: If AP patients show a distinct orointestinal microbiome dependent on the severity and course of the disease, microbiome sequencing could rapidly be implemented in the early clinical management of AP patients in the future.

trial registrationClinicalTrials.gov Identifier: NCT04777812.

Indexed as

MicrobiotaPancreatitisAcute DiseaseHumansMulticenter Studies as TopicPrognosisProspective StudiesRNA, Ribosomal, 16SSeverity of Illness IndexRNA, Ribosomal, 16SAcute pancreatitisBiomarkerMetagenomic sequencingMulticentricNCT04777812ONTOrointestinale microbiomeOxford nanopore technologiesP-MAPSProspectiveSeverity

Identifiers

PMID34332533
PMCPMC8325304
OpenAlexW3191121582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.